JP2020079331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020079331A5 JP2020079331A5 JP2020036818A JP2020036818A JP2020079331A5 JP 2020079331 A5 JP2020079331 A5 JP 2020079331A5 JP 2020036818 A JP2020036818 A JP 2020036818A JP 2020036818 A JP2020036818 A JP 2020036818A JP 2020079331 A5 JP2020079331 A5 JP 2020079331A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025018896A JP2025065367A (ja) | 2018-08-01 | 2025-02-07 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713211P | 2018-08-01 | 2018-08-01 | |
| US62/713,211 | 2018-08-01 | ||
| US201862764952P | 2018-08-17 | 2018-08-17 | |
| US62/764,952 | 2018-08-17 | ||
| US201862760204P | 2018-11-13 | 2018-11-13 | |
| US62/760,204 | 2018-11-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020025071A Division JP6672533B1 (ja) | 2018-08-01 | 2020-02-18 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025018896A Division JP2025065367A (ja) | 2018-08-01 | 2025-02-07 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020079331A JP2020079331A (ja) | 2020-05-28 |
| JP2020079331A5 true JP2020079331A5 (OSRAM) | 2022-08-09 |
Family
ID=67660420
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019142108A Active JP6672516B2 (ja) | 2018-08-01 | 2019-08-01 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2020025071A Active JP6672533B1 (ja) | 2018-08-01 | 2020-02-18 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2020036818A Pending JP2020079331A (ja) | 2018-08-01 | 2020-03-04 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2025018896A Pending JP2025065367A (ja) | 2018-08-01 | 2025-02-07 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019142108A Active JP6672516B2 (ja) | 2018-08-01 | 2019-08-01 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2020025071A Active JP6672533B1 (ja) | 2018-08-01 | 2020-02-18 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025018896A Pending JP2025065367A (ja) | 2018-08-01 | 2025-02-07 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20210301004A1 (OSRAM) |
| EP (2) | EP3829628B1 (OSRAM) |
| JP (4) | JP6672516B2 (OSRAM) |
| KR (5) | KR20200033348A (OSRAM) |
| CN (1) | CN112512563A (OSRAM) |
| AU (2) | AU2019315213B2 (OSRAM) |
| BR (1) | BR112021001655A2 (OSRAM) |
| CA (1) | CA3107618A1 (OSRAM) |
| CR (1) | CR20210103A (OSRAM) |
| DE (1) | DE112019003835T5 (OSRAM) |
| ES (1) | ES2980137T3 (OSRAM) |
| HR (1) | HRP20240823T1 (OSRAM) |
| HU (1) | HUE067057T2 (OSRAM) |
| IL (1) | IL280475B1 (OSRAM) |
| MX (2) | MX2021000516A (OSRAM) |
| MY (1) | MY210523A (OSRAM) |
| PH (1) | PH12021550226A1 (OSRAM) |
| PL (1) | PL3829628T3 (OSRAM) |
| RS (1) | RS65630B1 (OSRAM) |
| SG (1) | SG10202002898RA (OSRAM) |
| SM (1) | SMT202400271T1 (OSRAM) |
| TW (2) | TWI704157B (OSRAM) |
| WO (1) | WO2020027279A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| BR112013013354A2 (pt) | 2010-11-30 | 2020-10-06 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente |
| MY181199A (en) | 2014-12-19 | 2020-12-21 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| TWI617580B (zh) | 2014-12-19 | 2018-03-11 | 中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Ｉｌ−８関連疾患の治療用又は予防用組成物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2424379C (en) | 2000-10-10 | 2013-10-01 | Tanox, Inc. | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| CN100391537C (zh) | 2001-08-17 | 2008-06-04 | 建南德克公司 | 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂 |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CN103833854B (zh) | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | 免疫球蛋白变体及其用途 |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| MX2011001371A (es) | 2008-08-05 | 2011-06-16 | Novartis Ag | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complementos c5. |
| CA2742802C (en) | 2008-11-10 | 2019-11-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| BR112012022917A2 (pt) | 2010-03-11 | 2017-01-10 | Pfizer | anticorpos com ligação a antígeno dependente de ph |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| KR101638931B1 (ko) * | 2013-01-31 | 2016-07-12 | 서울대학교산학협력단 | 보체 관련 질환의 예방 및 치료를 위한 ｃ5 항체 및 방법 |
| TWI617580B (zh) * | 2014-12-19 | 2018-03-11 | 中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| RU2730590C2 (ru) * | 2015-02-27 | 2020-08-24 | Чугаи Сейяку Кабусики Кайся | Композиция для лечения заболеваний, связанных с ил-6 |
| EP3402816A1 (en) | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| MA53248A (fr) | 2016-01-25 | 2022-02-16 | Takeda Pharmaceuticals Co | Anticorps anti-c5 à commutation ph améliorée |
| JP7518764B2 (ja) * | 2017-10-26 | 2024-07-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与 |
| CA3084043A1 (en) * | 2017-12-04 | 2019-06-13 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
-
2019
- 2019-08-01 MX MX2021000516A patent/MX2021000516A/es unknown
- 2019-08-01 HU HUE19755447A patent/HUE067057T2/hu unknown
- 2019-08-01 EP EP19755447.0A patent/EP3829628B1/en active Active
- 2019-08-01 AU AU2019315213A patent/AU2019315213B2/en active Active
- 2019-08-01 DE DE112019003835.4T patent/DE112019003835T5/de active Pending
- 2019-08-01 CA CA3107618A patent/CA3107618A1/en active Pending
- 2019-08-01 WO PCT/JP2019/030283 patent/WO2020027279A1/en not_active Ceased
- 2019-08-01 MY MYPI2021000486A patent/MY210523A/en unknown
- 2019-08-01 TW TW109108378A patent/TWI704157B/zh active
- 2019-08-01 KR KR1020207007296A patent/KR20200033348A/ko not_active Ceased
- 2019-08-01 TW TW108127358A patent/TWI701041B/zh active
- 2019-08-01 RS RS20240695A patent/RS65630B1/sr unknown
- 2019-08-01 CN CN201980051238.8A patent/CN112512563A/zh active Pending
- 2019-08-01 ES ES19755447T patent/ES2980137T3/es active Active
- 2019-08-01 BR BR112021001655-4A patent/BR112021001655A2/pt unknown
- 2019-08-01 KR KR1020217009233A patent/KR20210038697A/ko not_active Ceased
- 2019-08-01 KR KR1020217009235A patent/KR20210037743A/ko not_active Ceased
- 2019-08-01 KR KR1020247023205A patent/KR20240115904A/ko active Pending
- 2019-08-01 SG SG10202002898RA patent/SG10202002898RA/en unknown
- 2019-08-01 US US17/263,691 patent/US20210301004A1/en active Pending
- 2019-08-01 HR HRP20240823TT patent/HRP20240823T1/hr unknown
- 2019-08-01 PL PL19755447.0T patent/PL3829628T3/pl unknown
- 2019-08-01 KR KR1020197036896A patent/KR20200033225A/ko not_active Ceased
- 2019-08-01 CR CR20210103A patent/CR20210103A/es unknown
- 2019-08-01 SM SM20240271T patent/SMT202400271T1/it unknown
- 2019-08-01 JP JP2019142108A patent/JP6672516B2/ja active Active
- 2019-08-01 EP EP24174873.0A patent/EP4445913A3/en active Pending
-
2020
- 2020-02-18 JP JP2020025071A patent/JP6672533B1/ja active Active
- 2020-03-04 JP JP2020036818A patent/JP2020079331A/ja active Pending
-
2021
- 2021-01-14 MX MX2025010400A patent/MX2025010400A/es unknown
- 2021-01-28 IL IL280475A patent/IL280475B1/en unknown
- 2021-01-29 PH PH12021550226A patent/PH12021550226A1/en unknown
-
2024
- 2024-08-02 AU AU2024205486A patent/AU2024205486A1/en not_active Abandoned
-
2025
- 2025-02-07 JP JP2025018896A patent/JP2025065367A/ja active Pending